Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort

• Published in: Drug design, development and therapy development and therapy, 2017-01, Vol.11, p.2131-2138
• Main Authors: Bernuth, Sebastian, Grimm, Daniel, Vollmar, Johanna, Darstein, Felix, Mittler, Jens, Heise, Michael, Hoppe-Lotichius, Maria, Galle, Peter R, Lang, Hauke, Zimmermann, Tim
• Format: Article
• Language: English
• Subjects: Aged; Anemia; Antiviral agents; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Antiviral drugs; Biopsy; Cohort Studies; DAA; direct acting antivirals; Drug therapy; Drug Therapy, Combination; Female; Gastroenterology; Genotype & phenotype; Genotypes; HCV; Hepacivirus - drug effects; Hepatitis; Hepatitis C; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Hepatology; Humans; Infections; Interferon; Kidney diseases; Laboratories; Liver; Liver Cirrhosis - etiology; Liver Cirrhosis - prevention & control; Liver diseases; Liver transplantation; Liver Transplantation - methods; Liver transplants; Male; Middle Aged; Original Research; Patient outcomes; Patients; Physiological aspects; Recurrence; Recurrent infection; Retrospective Studies; Ribavirin; Safety; Side effects; sofosbuvir; Survival; Survival Analysis; Therapy; Transplantation; Transplants & implants; Treatment Outcome; Viruses
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S139837

Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT. We retrospectively analyzed a cohort of 157 patients infected with HCV who underwent deceased donor LT between 1997 and 2014. Patient survival, outcome, and side effects of antiviral therapy were assessed. Survival with recurrent HCV genotype 1 (GT1) infection was inferior to other HCV GTs ( =0.01). The overall sustained virological response (SVR) rate with new DAA therapy was 94.6% (n=37). Patients with both GT1 and other GTs reached SVR rates >90%. We noticed a few side effects, mainly caused by ribavirin, and only one discontinuation in DAA-treated patients. DAA therapy was effective and safe in previous hard-to-treat patients after LT in this real-world cohort.